Global Cryptococcosis Market: Snapshot
One of the key factors driving the global cryptococcosis market is the increasing incidence of cryptococcosis infections across the world. The number of patients suffering from cryptococcosis has been found to be on the rise at a faster rate than previously thought. The patients suffering from the fungal infection are found to be in high numbers among HIV positive patients. Consequently, the growing number of HIV patients is also spurring the demand for advanced and effective treatment for the disease. Rising initiatives by government and non-government organizations is also putting the pipeline development in the global cryptococcosis market on the fast track in many countries, especially in developed ones. However, the global cryptococcosis market is currently being affected by restraining factors such as the increased mortality among cryptococcosis infected patients, which reduces the overall scope of testing and diagnostics, and the imminent patent expiry of key drugs which will result in the large scale entry of cheaper generics.
The global cryptococcosis market was valued at US$4.12 bn in 2015 and is projected to reach US$6.27 bn by 2024, after expanding at a CAGR of 4.8% from 2016 to 2024.
Middle East and Africa HIV Numbers Boost Demand for Cryptococcosis Treatment
The global cryptococcosis market is segmented into the key regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the leading share on the global cryptococcosis market for 2015, due to the rising prevalence of the infection in endemic areas of the U.S., coupled with a higher penetration of healthcare services across the country. The region is projected to continue to dominate the global cryptococcosis market till 2024, a fact attributed to the rising numbers of the HIV infected population in the region, a highly structured and advanced healthcare industry, and well-defined reimbursement policies from public as well as private health insurance firms.
The cryptococcosis market in the Middle East and Africa is projected to expand at a substantial growth rate owing to the contribution of Sub-Sahara African countries in terms of demand, where the count of HIV patients is exceptionally high. North America and the Middle East and Africa are projected to be highly lucrative regions in the global cryptococcosis market, while Europe, Asia Pacific, and Latin America expected to remain relatively smaller in terms of demand and growth rate.
Larger Demand for Cryptococcosis Treatment Generated from Retail Pharmacies
Based on the distribution channel, the global cryptococcosis market is segmented into hospital pharmacies, retail pharmacies, drug store, and mail order pharmacies. Retail pharmacy was the leading segment in the global market on the basis of revenue, for 2015. This segment is also expected to continue dominating the market till 2024, owing to the growing contribution of long-term medication needed for successful cryptococcosis treatment. Online purchase of drugs has been highly popular in a lot of developed economies, including the U.S. and Japan. Online pharmaceutical retailers are also generating a high volume of preference in in emerging economies such as Brazil, China, and India as well, further increasing the scope of growth for the global cryptococcosis market over the coming years.
The global cryptococcosis market is segmented on the basis of treatment, primarily into Amphotericin B, Flucytosine and Fluconazole. Amphotericin B further segmented into Amphocin, Fungizone, and other products. Flucytosine is further segmented into Ancobon and other products. Fluconazole includes Diflucan and other products. In terms of treatment, Flucytosine was the leading segment in the global cryptococcosis market in terms of revenue for 2015, driven by its large scale adoption in the U.S.
The leading players in the global cryptococcosis market so far, have included Bristol-Myers Squibb Company, Janssen Biotech, Inc. (Johnson & Johnson), Abbott Laboratories, Novartis AG, Pfizer, Inc., Valeant Pharmaceuticals, Inc., Glenmark Pharmaceuticals and Sigmapharm Laboratories LLC.
Global Cryptococcosis Market: Overview
This report on the global cryptococcosis market analyzes the current and future scenario of the global market. Cryptococcosis disease burden is rising due to increase in susceptible patient population such as HIV-infected patients, solid organ transplantation recipients, and other immunosuppressive hosts. In addition, the huge patient base in Sub-Saharan countries fuels the growth of the cryptococcosis market. For instance, According to CDC, it is estimated that around 1 million cryptococcal meningitis cases occurs globally. Also, it is also seen that cryptococcosis mortality burden is very high which results in around 625,000 deaths every year. In addition, rise in private and public funding for creating awareness, and favorable regulatory scenario for new product launch are boosting the growth of the global cryptococcosis market.
The cryptococcosis market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on treatment, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises clinical trial analysis and key industry event analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global cryptococcosis market.
Global Cryptococcosis Market: Scope of the Study
Based on treatment, the market is segmented into Amphotericin B, Flucytosine, Fluconazole, and other antifungals. Amphotericin B further segmented into Amphocin, Fungizone and other products. Flucytosine further segmented into Ancobon and other products. Fluconazole includes Diflucan and other products. In treatment type, Flucytosine was the largest segment of the global cryptococcosis market in terms of revenue in 2015, driven by its increasing adoption in U.S. The market segments have been analyzed based on cost-effectiveness of the drugs, prevalence of the diseases, and growing diagnosis rate of cryptococcosis across the globe. The market size and forecast for each of these segments have been provided for the period from 2014 to 2024, along with their respective CAGRs for the forecast period from 2016 to 2024, considering 2015 as the base year.
Based on distribution channel, the global cryptococcosis market is segmented as hospital pharmacies, retail pharmacies, drug store, and mail order pharmacies. Retail pharmacy was the largest segment of the global market in terms of revenue in 2015 and is expected to continue to dominate the market by 2024, which is attributed to the increasing contribution of long term medication required for cryptococcosis treatment. Online purchase of drugs has been highly popular in most of the developed economies such as the U.S. and Japan.
Geographically, the global cryptococcosis market has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa).
Global Cryptococcosis Market: Competitive Landscape
The report also profiles major players in the global cryptococcosis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Bristol-Myers Squibb Company, Janssen Biotech, Inc. (Johnson & Johnson), Abbott Laboratories, Novartis AG, Pfizer, Inc., Valeant Pharmaceuticals, Inc., Glenmark Pharmaceuticals and Sigmapharm Laboratories LLC.
The global cryptococcosis market has been segmented as given below:
Global Cryptococcosis Market, by Treatment,
- Amphotericin B
- Others (Voriconazole, surgery treatment, etc.)
Global Cryptococcosis Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Mail Order Pharmacies
Global Cryptococcosis market, by Region
- North America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America